Compare WSBF & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WSBF | RCEL |
|---|---|---|
| Founded | 1921 | N/A |
| Country | United States | United States |
| Employees | 593 | N/A |
| Industry | Savings Institutions | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.5M | 360.9M |
| IPO Year | 2013 | 2018 |
| Metric | WSBF | RCEL |
|---|---|---|
| Price | $19.48 | $12.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $12.16 |
| AVG Volume (30 Days) | 78.7K | ★ 262.4K |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | ★ 46.53 | 27.20 |
| EPS | ★ 0.84 | N/A |
| Revenue | N/A | ★ $71,610,000.00 |
| Revenue This Year | N/A | $21.81 |
| Revenue Next Year | $8.67 | $25.84 |
| P/E Ratio | $23.75 | ★ N/A |
| Revenue Growth | N/A | ★ 11.45 |
| 52 Week Low | $14.52 | $3.22 |
| 52 Week High | $21.66 | $12.23 |
| Indicator | WSBF | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 29.15 | 64.34 |
| Support Level | $19.06 | $3.74 |
| Resistance Level | $19.76 | N/A |
| Average True Range (ATR) | 0.48 | 0.60 |
| MACD | -0.15 | -0.04 |
| Stochastic Oscillator | 6.04 | 80.40 |
Waterstone Financial Inc is a holding company. Through its subsidiaries, it operates in two reportable segments: Community Banking and Mortgage Banking. The Community Banking segment provides consumer and business banking products and services to customers, which include various types of loans, deposits, and personal investment services. The Mortgage Banking segment involves residential mortgage loans for the primary purpose of sale in the secondary market. The majority of its revenue comes from the Community Banking segment.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.